Investment Rating - The report gives a "Buy" rating for the company, with a target price of HKD 43.37 based on a 26x P/E ratio for 2025 [3][5]. Core Insights - The company is a leading player in the traditional Chinese medicine (TCM) chain service sector in China, with a strong focus on AI integration and a robust growth trajectory [9][14]. - Revenue is projected to grow significantly, with estimates of HKD 30.2 billion in 2024, representing a 30.1% year-on-year increase, and a net profit of HKD 3.1 billion, up 21.6% [9][27]. - The TCM market is expected to expand, with a projected market size of HKD 2.97 trillion by 2030, driven by increasing demand for TCM services [38][42]. Financial Projections - The company forecasts earnings per share (EPS) of HKD 1.53, 1.81, and 2.24 for 2025, 2026, and 2027 respectively [3]. - Revenue is expected to reach HKD 5.72 billion by 2027, with a compound annual growth rate (CAGR) of 25% from 2025 to 2027 [3][9]. - The gross margin is projected to stabilize around 28% in the coming years, while the net profit margin is expected to slightly decline to 9.44% by 2027 [3][36]. Business Model and Market Position - The company operates a comprehensive OMO (Online-Merge-Offline) business model, integrating online and offline services to enhance customer engagement and service delivery [17][31]. - The TCM industry is characterized by high growth potential and low market concentration, with the top five players holding only 1.5% market share, indicating significant room for expansion [56]. - The company has established a strong network of renowned TCM practitioners, enhancing its competitive edge and service quality [9][38]. AI and Innovation - The company has been investing in AI since 2019, focusing on developing AI-assisted TCM solutions to improve service delivery and expand its market reach [9][38]. - Collaborations with institutions like West China Hospital and Baidu aim to accelerate the development of clinical applications for TCM [9][38]. Market Trends - The TCM market is benefiting from favorable policies and increasing public awareness of traditional medicine, with a projected CAGR of 12.9% from 2023 to 2028 [42][56]. - The demand for TCM services is driven by factors such as an aging population, rising chronic diseases, and a growing preference for natural and holistic treatment options [42][42].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 43.37 based on a 26x P/E ratio for 2025 [3][5]. Core Insights - The company is a leading player in the traditional Chinese medicine (TCM) chain service sector, with a strong AI strategy and significant growth potential. The revenue is projected to grow at a CAGR of 26.8% from 2018 to 2024, with 2024 revenue expected to reach HKD 30.2 billion, representing a 30.1% year-on-year increase [9][38]. - The TCM market in China is expected to grow significantly, with the market size projected to reach CNY 2.97 trillion by 2030, driven by factors such as an aging population and increasing public awareness of TCM [38][42]. Summary by Sections Company Overview - Established in 2010, the company has expanded its offline presence in major cities and developed an online platform, becoming a comprehensive TCM healthcare service provider [14][9]. - The company has achieved a stable business model integrating online and offline services, focusing on patient acquisition, consultation, diagnosis, and follow-up care [17][31]. Financial Performance - Revenue is forecasted to grow from HKD 2.32 billion in 2023 to HKD 5.72 billion in 2027, with a projected net profit of HKD 538.88 million in 2027 [3][4]. - The company has shown a consistent increase in adjusted net profit, with a forecasted growth of 31.4% in 2024 [27][36]. Market Potential - The TCM service market is characterized by high growth and low concentration, with the top five players holding only a 1.5% market share. The company currently holds a 0.2% market share, indicating significant room for growth [56][38]. - The demand for TCM services is driven by demographic changes, lifestyle diseases, and increasing cultural acceptance of TCM practices [42][38]. AI and Innovation - The company has been investing in AI since 2019, aiming to enhance TCM services and facilitate the internationalization of TCM products [9][3]. - Collaborations with institutions like West China Hospital and Baidu are underway to develop AI-assisted TCM solutions, which could revolutionize the delivery of TCM services [9][3]. Competitive Landscape - The TCM industry is fragmented, with many small players, creating opportunities for consolidation and growth for established companies like the one in the report [56][53]. - The regulatory environment is becoming increasingly favorable for private TCM institutions, promoting high-quality development in the sector [46][47].

军工上游进入配置区间，关注军贸和航发 产业链等 —军工行业周报（6/2~6/6） 核心观点 投资建议与投资标的 风险提示 军品订单和收入确认不及预期；研发进度及产业化不及预期；竞争格局及份额波动风 险；产品价格下降风险等。 国防军工行业 行业研究 | 行业周报 | | 看好（维持） | | --- | --- | | | 中国 | | | 国防军工行业 | | | 2025 年 06 月 09 日 | | 国家/地区 行业 报告发布日期 | | | 罗楠 | 021-63325888*4036 | | --- | --- | | | luonan@orientsec.com.cn | | | 执业证书编号：S0860518100001 | | 冯函 | 021-63325888*2900 | | | fenghan@orientsec.com.cn | | | 执业证书编号：S0860520070002 | 鲍丙文 baobingwen@orientsec.com.cn | OC 证落地，载人 eVTOL 迎来商业化元年 | 2025-03-30 | | --- | --- | | 全力推进"十四五"规划圆满 ...

固定收益 | 动态跟踪 可考虑牛陡交易 固定收益市场周观察 研究结论 高频数据跟踪：生产端，各行业开工率分化。需求端，乘用车厂家批发及厂家零售 同比增速高位回落。商品房成交面积同比增速处于较大波动中，6 月 8 日当周 30 大 中城市商品房销售面积下滑，同比增速为-33%左右。出口指数方面，SCFI、 CCFI 综合指数分别变动 8.1%、3.3%。价格端，原油价格上行，铜铝价格分化； 煤炭价格分化，动力煤活跃合约期货结算价与上周持平，焦煤活跃合约期货结算价 上行。中游方面，建材综合价格指数、水泥指数小幅下行，玻璃指数上行。螺纹钢 产量维持小幅下滑，库存较上周小幅下滑，期货价格抬升。下游消费端，蔬菜价格 上行，水果、猪肉价格均下滑。 风险提示 政策变化超预期；货币政策变化超预期；经济基本面变化超预期；信用风险暴露超预 期；数据统计可能存在遗误 报告发布日期 2025 年 06 月 09 日 | 齐晟 | qisheng@orientsec.com.cn | | --- | --- | | | 执业证书编号：S0860521120001 | | 杜林 | dulin@orientsec.com.cn | | ...

Investment Rating - The report maintains a "Positive" investment rating for the mechanical equipment industry [5] Core Viewpoints - The financing situation in the robot primary market remains strong, indicating an upward trend in industry prosperity. Vertical application scenarios are still crucial, with a focus on regional concentration. Short-term advantages lie in components, while the overall machine landscape is moving towards concentration [4][8][9] - The report suggests paying attention to segmented application fields, key regional companies, short-term components, and medium to long-term complete machine manufacturers [4][28] Summary by Sections Financing Trends - In the first five months of 2025, the number of financing projects in the robot sector showed a slight decline in May but remained at a good level. The financing for specialized robots accounted for over 50%, with humanoid and quadruped robots following closely [8][9][12] - Hardware financing is predominant, with a focus on hardware manufacturing. The number of hardware component financing projects exceeds that of software [8][20][27] Regional Analysis - The financing distribution shows that Shenzhen leads, with significant increases in Shanghai's financing in April and May 2025. This indicates a concentration of the humanoid robot industry chain in regions with existing advantages [8][9][24] Component vs. Complete Machine Dynamics - The report highlights that components currently hold a relative advantage, with supply still tight. However, the financing for complete machines is beginning to concentrate, suggesting a potential shift in industry dynamics [8][27][28] Recommended Companies - The report recommends focusing on the following companies: - Complete Machines and Assemblies: UBTECH, Yujian, Estun, Topstar, Efort-U, Zhongjian Technology, Yijiahe, Yongchuang Intelligent, Jack, Liyi Intelligent Manufacturing, Top Group, Sanhua Intelligent Control, Xinzhi Group [4][28] - Components: Wuzhou Xinchun, Beite Technology, Zhenyu Technology, Jinwo Shares, Green Harmonic, Siling Shares, Jiechang Drive, Zhaowei Electromechanical, Xiangxin Technology, Buke Technology, Nanshan Zhishang, Hanwei Technology, Lingyun Light [4][29] - Scenarios and Applications: Zhongyou Technology, Dema Technology, Yinfeng Storage, Anhui Helix, Hangcha Group, Noli Shares [4][29]

投资策略 | 定期报告 纷扰于外，求诸于内 报告发布日期 2025 年 06 月 08 日 | 张志鹏 | zhangzhipeng@orientsec.com.cn | | --- | --- | | 17 | 执业证书编号：S0860522020002 | | 张书铭 | 021-63325888*5152 | | | zhangshuming@orientsec.com.cn | | | 执业证书编号：S0860517080001 | | 美国"薛定谔式"关税扰动金融市场：— | 2025-06-02 | | --- | --- | | —策略周报 0531 | | | 进入政策观察期：——策略周报 0525 | 2025-05-25 | | 关税降级提振市场风险偏好：——策略周 | 2025-05-19 | | 报 0518 | | | 逆周期政策提振市场信心：——策略周报 | 2025-05-12 | | 0512 | | | 物来顺应：——策略周报 0505 | 2025-05-06 | 研究结论 风险提示 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部分，或请与您的投资代 ...

Quantitative Models and Factor Construction Factor Name: DELTAROE - **Construction Idea**: Measures the change in return on equity (ROE) over a specific period, reflecting the company's profitability dynamics[6][19][46] - **Construction Process**: - Calculate the difference in ROE between the current period and the previous period - Formula: $\Delta ROE = ROE_{current} - ROE_{previous}$[19][46] - **Evaluation**: Demonstrates strong performance across multiple indices, indicating its effectiveness in capturing profitability trends[6][46][49] Factor Name: Standardized Unexpected Earnings (SUE) - **Construction Idea**: Quantifies the deviation of actual earnings from expected earnings, standardized by the standard deviation of forecast errors[19] - **Construction Process**: - Formula: $SUE = \frac{E_{actual} - E_{expected}}{\sigma_{forecast\ errors}}$ - Where $E_{actual}$ is the actual earnings, $E_{expected}$ is the consensus forecast, and $\sigma_{forecast\ errors}$ is the standard deviation of forecast errors[19] - **Evaluation**: Effective in identifying earnings surprises, with positive performance in various market conditions[6][19] Factor Name: Trend - **Construction Idea**: Captures momentum by comparing short-term and long-term exponential weighted moving averages (EWMA) of stock prices[14] - **Construction Process**: - Two variations: - $Trend_{120} = \frac{EWMA_{halflife=20}}{EWMA_{halflife=120}}$ - $Trend_{240} = \frac{EWMA_{halflife=20}}{EWMA_{halflife=240}}$ - Where $EWMA$ is the exponentially weighted moving average with specified half-life[14] - **Evaluation**: Exhibits strong positive returns, indicating market preference for momentum strategies[9][11] Factor Name: Liquidity - **Construction Idea**: Measures stock liquidity through turnover rates and regression-based liquidity beta[14] - **Construction Process**: - Average log turnover over 243 days - Regression of individual stock turnover against market turnover to derive liquidity beta[14] - **Evaluation**: Mixed performance, with sensitivity to market conditions[10][14] Factor Name: Volatility - **Construction Idea**: Captures price fluctuations using various measures of historical volatility[14] - **Construction Process**: - Standard deviation of daily returns over 243 days - Range-based volatility: $Range = \frac{High_{243} - Low_{243}}{Low_{243}}$ - Maximum and minimum return averages over six days within 243 days[14] - **Evaluation**: Underperforms in high-volatility environments, indicating reduced investor appetite for risk[10][14] --- Factor Backtesting Results DELTAROE - **Performance**: - CSI 300: Weekly return 0.41%, monthly return 1.59%[6][22] - CSI 500: Weekly return 0.95%, monthly return 1.19%[6][26] - CSI 800: Weekly return 1.08%, monthly return 1.62%[6][30] - CSI 1000: Weekly return 1.79%, monthly return 1.54%[6][34] - CNI 2000: Weekly return 4.71%, monthly return 7.07%[6][37] - CSI All Share: Weekly return 1.84%, monthly return 2.41%[6][46] Standardized Unexpected Earnings (SUE) - **Performance**: - CSI 500: Weekly return 1.20%, monthly return 1.59%[6][26] - CSI 800: Weekly return 0.34%, monthly return 0.98%[6][30] - CNI 2000: Weekly return 1.65%, monthly return 14.68%[6][37] - CSI All Share: Weekly return 0.96%, monthly return 1.14%[6][46] Trend - **Performance**: - Weekly return 1.15%, monthly return 4.58%, annualized return 19.73%[9][11] Liquidity - **Performance**: - Weekly return -0.43%, monthly return -3.25%, annualized return 37.53%[10][11] Volatility - **Performance**: - Weekly return -0.95%, monthly return -2.71%, annualized return 31.87%[10][11] --- MFE Portfolio Construction - **Optimization Model**: - Objective: Maximize single-factor exposure - Formula: $\begin{array}{ll}max&f^{T}w\\ s.t.&s_{l}\leq X(w-w_{b})\leq s_{h}\\ &h_{l}\leq H(w-w_{b})\leq h_{h}\\ &w_{l}\leq w-w_{b}\leq w_{h}\\ &b_{l}\leq B_{b}w\leq b_{h}\\ &0\leq w\leq l\\ &1^{T}w=1\\ &\Sigma|w-w_{0}|\leq to_{h}\end{array}$[61][62] - Constraints: - Style and industry exposure limits - Stock weight deviation limits - Turnover rate limits[64][65] - **Backtesting**: - Monthly rebalancing - Transaction cost: 0.3% per side - Metrics: Historical returns, risk-adjusted performance[65]

Investment Rating - The industry investment rating is "Buy" for companies with strong fundamentals and low correlation to oil prices, suggesting a bottom-fishing strategy [10][18]. Core Viewpoints - The report indicates a recovery in macro expectations, with a notable increase in oil prices due to supply risks from geopolitical tensions and seasonal demand [10][14]. - The report emphasizes the importance of focusing on domestic demand and opportunities in new material substitutions, particularly in the agricultural chemical sector during the spring planting season [10][18]. Summary by Sections 1. Core Viewpoints - Oil prices have risen this week, with a focus on companies that have strong fundamentals and are less affected by oil price fluctuations [10][18]. - Recommendations include companies like Wanhua Chemical, Huamao Technology, Runfeng Co., Guoguang Co., and Hualu Hengsheng, highlighting their unique market positions and growth potential [10][18]. 2. Oil and Chemical Price Information 2.1 Oil - As of June 6, Brent oil prices increased by 4.02% to $66.47 per barrel, driven by supply risks and seasonal demand [14]. - U.S. crude oil commercial inventories decreased by 4.3 million barrels to 436.1 million barrels [14]. 2.2 Chemicals - Among 188 monitored chemical products, the top three price increases this week were for liquid chlorine (up 11.8%), natural gas (up 9.3%), and hydrochloric acid (up 4.6%) [15]. - The report notes significant monthly price changes, with hydrochloric acid increasing by 54.5% [10][15]. 3. Price and Spread Changes - The report highlights the top three products with the largest weekly spread increases: R410a spread (up 200.0%), acrylic acid butyl ester spread (up 58.2%), and PTA (up 45.9%) [10][20]. - Monthly spread changes show significant increases in the electric stone method PVC spread (up 216.9%) [10][20].

投资策略 | 定期报告 报告发布日期 2025 年 06 月 08 日 | 张志鹏 | zhangzhipeng@orientsec.com.cn | | --- | --- | | 17 | 执业证书编号：S0860522020002 | | 张书铭 | 021-63325888*5152 | | | zhangshuming@orientsec.com.cn | | | 执业证书编号：S0860517080001 | | 美国"薛定谔式"关税扰动金融市场：— | 2025-06-02 | | --- | --- | | —策略周报 0531 | | | 进入政策观察期：——策略周报 0525 | 2025-05-25 | | 关税降级提振市场风险偏好：——策略周 | 2025-05-19 | | 报 0518 | | | 逆周期政策提振市场信心：——策略周报 | 2025-05-12 | | 0512 | | | 物来顺应：——策略周报 0505 | 2025-05-06 | 纷扰于外，求诸于内 研究结论 风险提示 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部分，或请与您的投资代 ...

产业链数据跟踪 投资建议与投资标的 ⚫ 文化纸步入行业淡季，浆纸价格下行，推荐林浆纸一体化行业龙头太阳纸业 (002078，买入)。同时建议关注特种纸领军企业仙鹤股份(603733，买入)，中高端 装饰原纸龙头华旺科技(605377，买入)以及食品包装纸细分龙头五洲特纸(605007， 增持)。废纸系纸种方面，展望 2025 年行业新增供给增速明显放缓，整体供需有望 逐步改善，推荐玖龙纸业(02689，买入)、山鹰国际(600567，增持)。 风险提示 造纸轻工行业 行业研究 | 行业周报 本周成品纸价格基本稳定 ——造纸产业链数据每周速递（2025/06/06） 核心观点 ⚫ 本周轻工制造行业指数上涨 2.18%，跑赢大盘 1.30pct；造纸子板块上涨 1.78%， 跑赢大盘 0.90pct。本周沪深 300 指数上涨 0.88%，轻工制造(申万)指数上涨 2.18%，跑赢大盘 1.30pct，在 28 个申万一级行业中位列第 8 位；二级行业中，造 纸子板块上涨 1.78%，跑赢大盘 0.90pct。本周轻工四大子板块按涨幅由大到小分别 为文娱用品、家具、造纸和包装印刷板块，分别上涨 5.51%、2.0 ...